Table 3.
Grading the evidence with GRADEpro Guideline Development Tool.
| Certainty assessment |
No. of patients |
Effect |
Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Baricitinib | Control | Relative (95% CI) | Absolute (95% CI) | ||
| Mortality | ||||||||||||
| 3 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 106/1330 (8.0%) | 166/1329 (12.5%) | RR 0.64 (0.51–0.79) | 45 fewer per 1000 (from 61 fewer to 26 fewer) |
⨁⨁⨁⨁ High |
CRITICAL |
| Mortality | ||||||||||||
| 11 | Observational studies | Not serious | Not serious | Not serious | Not serious | None | 102/967 (10.5%) | 157/975 (16.1%) | RR 0.58 (0.45–0.73) | 68 fewer per 1000 (from 89 fewer to 43 fewer) |
⨁⨁◯◯ Low |
CRITICAL |
| Disease progression | ||||||||||||
| 2 | Randomised trials | Not serious | Seriousa | Not serious | Seriousb | None | 171/1225 (14.0%) | 206/1222 (16.9%) | RR 0.80 (0.58–1.10)< | 34 fewer per 1000 (from 71 fewer to 17 more) |
⨁⨁◯◯ Low |
CRITICAL |
| Disease progression without 2 PB articles | ||||||||||||
| 8 | Observational studies | Not serious | Not serious | Not serious | Not serious | None | 44/689 (6.4%) | 79/733 (10.8%) | RR 0.54 (0.37–0.78) | 50 fewer per 1000 (from 68 fewer to 24 fewer) |
⨁⨁◯◯ Low |
CRITICAL |
CI: confidence interval; RR: risk ratio; PB: publication bias.
Explanation.
a
No agreement between 2 studies where one said yes and one said no to BDP.
b
Based on optimal information size (OIS) calculation; the OIS did not achieve.